{"id":1358,"date":"2020-11-20T10:29:00","date_gmt":"2020-11-20T13:29:00","guid":{"rendered":"https:\/\/revista.suryamkt.com.br\/?p=1358"},"modified":"2022-02-09T10:32:48","modified_gmt":"2022-02-09T13:32:48","slug":"predictive-factors-for-loss-of-response-to-anti-tnf-in-crohns-disease","status":"publish","type":"post","link":"https:\/\/revistaabcd.org.br\/pt-br\/predictive-factors-for-loss-of-response-to-anti-tnf-in-crohns-disease\/","title":{"rendered":"PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN\u2019S DISEASE"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Background:<\/h2>\n\n\n\n<p>Anti-TNF drugs are a fundamental part of the treatment of Crohn\u2019s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Aim:<\/h2>\n\n\n\n<p>Identify potential factors related to loss of response to anti-TNF agents in Crohn\u2019s disease patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Methods:<\/h2>\n\n\n\n<p>This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p&lt;0.05.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Results:<\/h2>\n\n\n\n<p>Sixty-four patients were included, most of them females (56.3%), predominant age group between 26 and 55 years, of whom 25 required optimization, 23 remained in remission with the usual dose and interval, and 16 required switch; most of those who needed switch had hematological problems such as anemia and\/or had already undergone surgical treatment for CD.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusions:<\/h2>\n\n\n\n<p>Anemia and prior CD surgery have been linked to loss of anti-TNF response.<\/p>","protected":false},"excerpt":{"rendered":"<p>Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn\u2019s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn\u2019s disease patients. Methods: This is a prospective study of CD patients attending [&hellip;]<\/p>","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[9],"tags":[338,337,255,339],"class_list":["post-1358","post","type-post","status-publish","format-standard","hentry","category-original-article","tag-adalimumab","tag-crohn-disease","tag-infliximab","tag-treatment-failure"],"acf":[],"modified_by":"Roni","_links":{"self":[{"href":"https:\/\/revistaabcd.org.br\/pt-br\/wp-json\/wp\/v2\/posts\/1358"}],"collection":[{"href":"https:\/\/revistaabcd.org.br\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/revistaabcd.org.br\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/revistaabcd.org.br\/pt-br\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/revistaabcd.org.br\/pt-br\/wp-json\/wp\/v2\/comments?post=1358"}],"version-history":[{"count":0,"href":"https:\/\/revistaabcd.org.br\/pt-br\/wp-json\/wp\/v2\/posts\/1358\/revisions"}],"wp:attachment":[{"href":"https:\/\/revistaabcd.org.br\/pt-br\/wp-json\/wp\/v2\/media?parent=1358"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/revistaabcd.org.br\/pt-br\/wp-json\/wp\/v2\/categories?post=1358"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/revistaabcd.org.br\/pt-br\/wp-json\/wp\/v2\/tags?post=1358"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}